What To Say About Tumor Treating Fields Mesothelioma To Your Mom

Tumor Treating Fields Mesothelioma

Tumor treating mesothelioma caused by fields is a new kind of therapy that uses alternating electric fields to slow the growth of cancer. It is used in combination with chemotherapy to treat the pleural cancer.

Following the success of the STELLAR study after the STELLAR study, the FDA approved TTFields together with pemetrexed cisplatin. In 2019 FDA approved TTFields. Patients may ask their doctor for this treatment.

Disrupting Cell Division

TTFields use different electrical fields to disrupt cancer cell proteins and block the cells from dividing. This can stop phoenix mesothelioma treatment from expanding or forming in other organs. TTFields also work to stimulate the production of proteins that kill cancer cells and help the immune system fight mesothelioma sarcomatoid treatment tumors.

During treatment, the patient wears a small device with insulated pads that adhere to the skin. The device is able to deliver a low-intensity electrical current, and patients are able to decide the extent of treatment of mesothelioma guidelines they receive. A mesothelioma therapy session lasts approximately 30 minutes. Patients can have TTFields treatment at various times throughout the day.

A TTFields research study published in 2021 found that the intensity of the electrical field of 100-300 kilohertz was able to stop the division of cancer cells and cause them to die. The study included different types of cancer cells and found that electrical fields killed all of them, regardless of the cellular structure.

The study's author recommended mixing TTFields with chemotherapy for mesothelioma. Novocure's TTFields product, NovoTTF-100L, was approved by the FDA in the year 2019 to treat unresectable pleural mesothelioma. It is now available through mesothelioma specialists in accredited medical centers in the U.S. including the West Cancer Center, Memphis. The NovoTTF 100L device, also referred to as Optune Lua has been used to treat mesothelioma when it is combined with platinum-based chemotherapy and pemetrexed. Mesothelioma patients have reported longer survival when the TTFields therapy is paired with chemotherapy.

Another study published in the journal "Lung Cancer" reported that TTFields therapy works well in conjunction with chemotherapy. In the trial, researchers discovered that combining chemotherapy and TTFields reduced the number of mesothelioma cancerous cells in animal models by more than 80%. The study also revealed that combing these treatments boosted the production proteins that kill mesothelioma tumor cells and reduce the amount of cancerous DNA that is found in your body.

The TTFields treatment is a relatively new treatment and many mesothelioma doctors do not offer it for patients with pleural malignant mesothelioma. Patients can still have access to this treatment through clinical trials, or at clinics that are certified by Novocure for mesothelioma.

Stalling Tumor Growth

When mesothelial cancer cells multiply and exceed their normal lifespan they transform and may cause an overabundance that grows and expands throughout the body. Treatment for tumors prevents mesothelial cells from duplication and prevent mesothelioma expanding and asbestos mesothelioma Treatment growing.

The TTFields device, worn on the chest as a vest produces a series of electrical field that disrupt protein and cancer cells and slow the growth of tumors. The device comes with insulated pads that stick to the skin. Patients or health professionals are able to apply them at home.

Doctors suggest mixing TTFields treatment with chemotherapy for the best results. The combination boosts production of proteins that kill cancerous cells, and reduces cancer cells' ability to repair DNA damage caused by chemotherapy drugs. This allows chemotherapy drugs to perform more effectively and improves the survival rate in mesothelioma patients.

In the STELLAR trial, which was conducted in 2017 TTFields therapy combined with chemotherapy significantly improved survival for mesothelioma patients. In the year 2019 the FDA approved the NovoTTF 100L System, now being sold under the brand name Optune Lua for use with pemetrexed, cisplatin, or carboplatin, as a first-line treatment for malignant pleural melanomas that is not surgically resectable.

Researchers have discovered that the TTFields therapy is effective against mesothelioma due to its interception of cell division. The treatment TTFields induces cancer cells to break up in a process known as mitosis. The cell debris is absorbed by surrounding tissues, which hinders the growth of new tissue. Mitosis also blocks mesothelioma cells from repairing damaged DNA and makes the cells more sensitive to radiation treatments.

The TTFields therapy also decreases the flow of blood to tumors through the suppression of vascular endothelial-growth factor (VEGF) and the increase of hypoxia-inducible factors-1 alpha or HIF-1a. HIF-1a is associated with cancer cells angiogenesis.

If you are diagnosed with mesothelioma, speak to your doctor about TTFields and whether it is the right treatment for you. Novocure and mesothelioma experts are conducting clinical trials to evaluate the efficacy of TTFields. To find out more about how mesothelioma-TTFields might help your treatment plan get in touch with a Novocure certified specialist at one of more than 1,300 U.S. treatment centers.

Killing Tumor Cells

Tumor-treating fields for treating tumors (TTFields), which send electrical waves throughout the body. They disrupt cell division and eliminate cancer cells. They are low-intensity and medium frequency electrical fields that alternatingly target cancerous cells without harming healthy cells. These electric fields also reduce DNA repair and boost cellular defenses to make it more difficult for cancerous cells to survive. TTF is non-invasive, and has only mild adverse effects.

Scientists believe TTFields work by interrupting mitosis, a process by which the cell divides into two identical new cells. Normal cells have controls in place to limit mitosis however cancerous malignancies breach this control and multiply at a runaway pace. TTFields interferes with this process by blocking the signals that regulate mitosis in asbestos mesothelioma treatment (news) cancer cells. In the STELLAR trial TTFields in conjunction with chemotherapy increased survival rates for mesothelioma. Mesothelioma survivors who received TTFields together with maintenance cycles of chemotherapy survived an average of six months longer than those who received only chemotherapy.

In a different study, it was discovered that TTFields could increase the effectiveness of certain chemotherapy drugs known as platinum-based treatments. These platinum-based therapies kill mesothelioma through targeting mitochondria. This is where cancerous cell energy comes from. When TTFields are combined with these chemotherapies, the combination may result in greater DNA damage and faster death of cancer cells.

In some cases, TTFields may also enhance the effects of radiation treatment. Scientists have observed that combining TTFields with radiation therapy may create an "synergistic effect." This means that the combination treatments increase the sensitivity of mesothelioma tumor cells to radiation.

The TTFields treatment is currently only available in certain mesothelioma centres. However, a mesothelioma expert can determine whether you may be eligible for this treatment. If you qualify an attorney for mesothelioma can assist you in obtaining treatment for stage 3 mesothelioma that incorporates TTFields along with chemotherapy. If you're an active military veteran mesothelioma lawyer will assist you in obtaining treatment that is covered under your VA health benefits.

Side Effects

The TT fields therapy can disrupt the cancer cells by creating a field of electricity that interferes with their ability to divide. This could slow the growth of tumors, and also prevent the spread of cancer to other parts of the body. The TT fields device is noninvasive, which means it doesn't damage surrounding tissue or cause discomfort. This is in contrast to traditional chemotherapy, which involves intravenous injections or radiation, both of which could cause serious side effects.

In an experiment, patients who received a combination of TT fields and temozolomide saw survival gains comparable to those who were treated only with chemo. Doctors attributed this improved survival to TT fields, which increase the efficacy of chemotherapy while reducing the risk of side effects.

Mesothelioma cells may transform into cancerous cells and reproduce uncontrollably to form an aggressive tumor that takes over the organs of your body. By interrupting cell division, mesothelioma treatments like TT fields stop mesothelioma cells from replicating and inhibiting your body's normal functions.

In a mesothelioma study, mesothelioma patients who received TT fields in conjunction with their chemo had an average survival of 18.2 months. Those who received TT fields, but not chemotherapy had a survival rate of 12.1.

The pleura or thin lining of your lungs can be treated by applying treatment fields to your abdominal wall or chest. The device is small and can be worn for up to 18 hours and even during sleep. Patients can live their lives and work while undergoing treatment.

The TT fields are a great complement with traditional chemotherapy or immunotherapy as well as other mesothelioma treatments. Mesothelioma patients who are interested in TT fields should discuss this option with their mesothelioma physician who will explain the eligibility requirements and benefits for the patient's individual case.